These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32073428)

  • 1. Triglycerides and residual risk.
    Vallejo-Vaz AJ; Corral P; Schreier L; Ray KK
    Curr Opin Endocrinol Diabetes Obes; 2020 Apr; 27(2):95-103. PubMed ID: 32073428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
    Picard F; Steg PG
    Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
    Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
    Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
    Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
    Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
    Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
    Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
    [No Abstract]   [Full Text] [Related]  

  • 8. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
    Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
    Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
    Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
    Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments.
    Reyes-Soffer G
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):85-89. PubMed ID: 33481422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
    Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
    Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
    Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
    Scherer DJ; Nicholls SJ
    Vasc Health Risk Manag; 2015; 11():203-9. PubMed ID: 25848301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes.
    Alexopoulos AS; Qamar A; Hutchins K; Crowley MJ; Batch BC; Guyton JR
    Curr Diab Rep; 2019 Feb; 19(4):13. PubMed ID: 30806837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.